ClinicalTrials.gg
Active, not recruitingNCT06142071SALUTEUpdated Jul 17, 2024

Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting

An observational study in Cancer, sponsored by Swansea Bay University Health Board. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Swansea Bay University Health Board · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The main questions the study aims to answer are:

  1. The proportion of family members of cancer patients who say they need more support
  2. What support family members feel would be beneficial

Information about patients' cancer diagnosis and treatment will be collected from their medical notes.

Participating family members will be asked to complete a telephone questionnaire. Selected family members may also be asked to participate in an optional follow-up interview.

Read the detailed description

When someone is diagnosed with cancer, it can be a worrying and stressful time for patients and for their family members. Family members may provide practical and emotional support to patients, and may take on a caregiver role.

Family members may want more information or advice, or may benefit from emotional support themselves. The study aims to identify any gaps in the current support provided to family members so that services can be improved in the future.

Oncology patients in Singleton Hospital, Swansea will be asked by their oncology team to identify one or more family members to participate in the study. If a family member agrees to participate in the study, the research team will call them to complete a telephone questionnaire. The questionnaire should take less than 20 minutes and asks them some general questions (e.g. age, gender) and some questions about how they are feeling, what support services they find helpful and what additional support they feel would be beneficial.

Data regarding participating patients' cancer diagnosis and treatment will be collected from their medical notes.

After the questionnaire data has been analysed, optional follow-up interviews will be conducted with some family members to explore any issues identified in greater detail.

Patients and family members will be recruited during a 6 month recruitment period and all responses will be anonymised.

This is a pilot study which will not change the current support provided to family members, although they may be directed to existing services if appropriate. Patients' treatment will not be changed in any way.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Swansea Bay University Health Board is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Oncology patients in South West Wales, United Kingdom

Eligibility criteria

Inclusion Criteria for patients

  • diagnosed with a solid organ under the care of the oncology team
  • able to identify at least one family member who may be willing to participate in the study

Inclusion Criteria for family members

  • a family member of a patient diagnosed with a solid organ malignancy under the care of the oncology team

Exclusion Criteria for patients and family members

  • medical or psychiatric condition impairing ability to consent
  • the patient's treating oncologist's opinion is that participating in the study would cause severe distress to the patient or their family
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • BehavioralTelephone questionnaire

    Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial

06

What researchers measure

Primary outcomes

  1. The proportion of family members who state they need more support

    The proportion of family members who state they need more support

    Time frame: 6 months after start of study recruitment

Secondary outcomes

  1. The proportion of family members who state they need more support with each of the Carer Support Needs Assessment Tool (CSNAT) domains

    he proportion of family members who state they need more support with each of the Carer Support Needs Assessment Tool (CSNAT) domains

    Time frame: 6 months after start of study recruitment

  2. Types of additional support that family members feel would be beneficial as identified via the telephone questionnaires and interviews

    This will be determined by qualitative analysis of questionnaire and interview data and may include improved psychological support, online resources, information leaflets etc

    Time frame: 6 months after start of study recruitment

07

Study locations

1 site
  • South West Wales Cancer Centre
    Swansea, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Sep 2024, 8 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 8 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 21, 2023
StartActual
Jan 8, 2024
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2024
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06142071
Lead sponsor
Swansea Bay University Health Board
Collaborators
Swansea University
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Jan 8, 2024
Primary completion
Sep 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Jul 17, 2024

Study contacts

Sing Yu Moorcraft
principal investigator · Swansea Bay University Health Board

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion